Candesartan for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Candesartan for Health & Longevity

Created on 06/16/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A long-established, low-cost blood-pressure medicine that relaxes blood vessels by blocking a pressure-raising hormone signal. Best-supported for reliable 24-hour blood-pressure lowering and fewer deaths and hospitalizations in people with a weakened heart, plus solid migraine prevention. Claims of organ protection beyond pressure lowering remain unsettled. (Full Review)

Protocol

Standard Dose
8–16 mg once daily
Titrated to a usual range of 16–32 mg once daily based on blood-pressure response; heart failure starts low at 4 mg daily.
Dosing Frequency
Single once-daily dose
Tight, slowly reversible receptor binding gives a long functional duration; can be taken at any consistent time, with some favoring evening dosing.
Titration
Increase every 2–4 weeks
Low starting dose with gradual titration reduces first-dose low blood pressure and dizziness; correct volume depletion before initiation.
Time to effect
Blood-Pressure Reduction
1–2 weeks
Begins within 1–2 weeks; the full effect of a given dose is generally reached by 4 weeks.
Migraine Prevention
8–12 weeks
Migraine-prevention benefit, where it occurs, is typically judged over 8–12 weeks.

Benefits

Contraindications
  • Pregnancy (second and third trimesters)
  • History of angioedema from a renin-angiotensin blocker
  • Bilateral renal artery stenosis
  • Severe liver impairment (Child-Pugh Class C)
  • Uncorrected volume depletion
  • Aliskiren in diabetes/kidney impairment
    •
Key Interactions
  • Other renin-angiotensin system blockers (ACE inhibitors, aliskiren)
  • Potassium-sparing diuretics and potassium supplements (spironolactone, eplerenone, amiloride, triamterene)
  • NSAIDs (ibuprofen, naproxen, diclofenac)
  • Lithium
  • Other blood-pressure-lowering supplements and drugs (fish oil, garlic extract, magnesium, CoQ10, L-arginine, beetroot/nitrate)
  • Trimethoprim-containing antibiotics
    •

Risk & Side Effects

  • High: Hypotension and dizziness; hyperkalemia; acute kidney function decline
    •
  • Medium: Fetal toxicity; fatigue and headache
    •
  • Low: Angioedema; liver enzyme elevation and hepatic injury
    •
  • Speculative: Cancer risk
    •

Monitoring

Marker Target Why
Blood pressure ~115–120 / 75–80 mmHg Primary efficacy target
Serum potassium 4.0–4.8 mmol/L Detects hyperkalemia (high potassium)
Serum creatinine Stable, <30% rise from baseline Detects acute kidney-function decline
eGFR >90 mL/min/1.73 m² (age-adjusted) Kidney filtering capacity
Fasting glucose / HbA1c Glucose <90 mg/dL; HbA1c <5.4% Context for diabetic kidney/benefit profile
Uric acid <5.5 mg/dL (men), <5.0 mg/dL (women) Context marker influenced by renin-angiotensin therapy

Cadence: Recheck kidney function and potassium within 1–2 weeks of starting or any dose increase; reassess blood pressure at 2–4 weeks; once stable, every 6–12 months (more often in older adults, diabetics, or those with reduced kidney function).

Qualitative Assessment

  • Absence of dizziness, lightheadedness, or fainting on standing
  • Stable energy levels without new persistent fatigue
  • For migraine users, a clear reduction in monthly headache days and attack severity
  • No new swelling of the face, lips, or tongue (which would signal angioedema)
  • Consistent, well-tolerated home blood-pressure readings without symptomatic lows
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.